A success for Seres
Seres finally is seeing some success for its C. difficile treatment that works by tinkering with the microbiome. About 11% of patients who took Seres’ drug, which is a pill filled with bacteria, had a recurrence a C. difficile infection — compared to 41% among those who didn’t take the drug.
This data represent a major comeback for Seres: Four years ago, the company reported a devastating — and unexpected — clinical trial failure that dropped its stock from $34 a share to less than $5. The company has since revised its screening protocols for trial participants, to try and ensure they indeed have C. difficile infections — and that may have helped tipped the balance in a positive direction.
This data represent a major comeback for Seres: Four years ago, the company reported a devastating — and unexpected — clinical trial failure that dropped its stock from $34 a share to less than $5. The company has since revised its screening protocols for trial participants, to try and ensure they indeed have C. difficile infections — and that may have helped tipped the balance in a positive direction.
.png)
No hay comentarios:
Publicar un comentario